AD-1211

AD-1211
Clinical data
Other names	AD-1211
ATC code	none;
Identifiers
	IUPAC name 1-(3-Methyl-2-butenyl)-4-[(1R)-1-phenyl-2-(3-hydroxyphenyl)ethyl]piperazine;
CAS Number	83374-58-7 ; 61311-01-1 (R)-enantiomer;
PubChem CID	173526;
ChemSpider	26286944 ;
UNII	7YT87DVF55;
CompTox Dashboard (EPA)	DTXSID00997906 ;
Chemical and physical data
Formula	C23H30N2O
Molar mass	350.506 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1c(O)cccc1CC(c3ccccc3)N(CC2)CCN2C\C=C(\C)/C;
	InChI InChI=1S/C23H30N2O/c1-19(2)11-12-24-13-15-25(16-14-24)23(21-8-4-3-5-9-21)18-20-7-6-10-22(26)17-20/h3-11,17,23,26H,12-16,18H2,1-2H3/t23-/m1/s1 ; Key:WLHCNEPBQJOHKW-HSZRJFAPSA-N ;
	(verify)

AD-1211 is an opioid analgesic drug invented in the 1970s by Dainippon Pharmaceutical Co. It is chemically a 1-substituted-4-prenyl-piperazine derivative, which is structurally unrelated to most other opioid drugs. The (S)-enantiomers in this series are more active as opioid agonists, but the less active (R)-enantiomer of this compound, AD-1211, is a mixed agonist–antagonist at opioid receptors with a similar pharmacological profile to pentazocine,^[1] and has atypical opioid effects with little development of tolerance or dependence seen after extended administration in animal studies.^[2]^[3]